Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Approved

Current status date:

2018-10-26

Product name:

FOLOTYN

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02481855

Product Monograph/Veterinary Labelling:

Date: 2018-10-19 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

SERVIER CANADA INC
270 3224 Avenue Jean-Béraud
Laval
Quebec
Canada H7T 2S4

Class:

Human

Dosage form(s):

Solution

Route(s) of administration:

Intravenous

Number of active ingredient(s):

1

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

10:00.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

L01BA05 PRALATREXATE%

Active ingredient group (AIG) number:See footnote5

0160770001

List of active ingredient(s)
Active ingredient(s) See footnote8 Strength
PRALATREXATE 40 MG / 2 ML

Risk Management Plans See footnote 7

A Risk Management Plan (RMP) for this product was submitted.

Version 4.0.3

"Page details"

Date modified: